ClinicalTrials.gg
CompletedNCT01540903Updated Sep 10, 2014

Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults

A Phase 1 interventional study of PfSPZ Challenge and Saline in Malaria, sponsored by Sanaria Inc.. Completed at 1 site in Tanzania. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-10.

Sponsored by Sanaria Inc. · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing PfSPZ Challenge in Malaria — 1 open to participants now, 1 under way, none of them phase 3. PfSPZ Challenge · Malaria.

Enrollment
7th of 13
30 · median 30
Started
2012
with 3 others
Phase 1
11 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
10 of 13
Sanaria Inc.

Among the 13 studies testing PfSPZ Challenge in Malaria, this one is the 7th largest by enrollment, is one of 4 that started in 2012, is one of 11 in phase 1, and was the 2nd registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

1 of the 13 studies testing PfSPZ Challenge in Malaria is open now. Recruiting first, the newest first:

About PfSPZ Challenge

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 20 Years to 35 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing PfSPZ Challenge in Malaria, or all of them as a file.
02

Study summary

The proposed trial will evaluate whether relatively non immune populations in endemic countries can be effectively infected with aseptic, purified, cryopreserved sporozoites (PfSPZ Challenge) given intradermally.

Read the detailed description

Controlled human malaria infection (CHMI) is a critical component of malaria vaccine and drug development and is an important element of any strategy for accelerating the development of new tools for malaria control, elimination and eradication. Until now, CHMI has been performed in malaria naïve subjects from countries not endemic for malaria using both infectious mosquitoes and recently, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ). Results from these studies report significant infection success in all study subjects and an excellent safety profile.

The conduct of CHMI studies in malaria endemic populations will allow early understanding of responses to new vaccines and drugs in endemic country populations and for direct comparisons between previously exposed and non-exposed individuals. Performing CHMI studies in malaria endemic countries will reduce associated costs, speed-up the process of testing and substantially contribute to the acceleration of the malaria vaccine and drug research and development processes.

This study to be conducted in Bagamoyo, Tanzania, aims to see whether people in endemic countries with minimal previous history of malaria are suitable for CHMI using PfSPZ Challenge. This study will also assess whether the success rate of the experiment is improved by lowering the volume of injection and increasing the number of inoculations. Hence, the study will contribute towards improvements in the CHMI studies using syringe and needle inoculation of sporozoites.

03

Conditions studied

  • Malaria

Keywords

  • Malaria Challenge
  • Plasmodium falciparum
  • PfSPZ Challenge
  • Controlled
  • human
  • malaria infection
04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Male aged between 20-35 years, healthy volunteers
  • Good Health status based on history \& clinical examination
  • Residing in or near DaresSalaam
  • Willing to contribute to science in Tanzania
  • Free from malaria parasite by blood smear \& qRT-PCR
  • Not suffering from any chronic illness including /AIDS
  • No documented history of malaria infection for the past 5 yrs
  • Able \& willing to come for complete one year follow up including minimum of three weeks of hospitalization
  • All volunteers must sign the form \& answer correctly 15 out 15 questions demonstrating their understanding of the meaning \& procedures of the study
  • Volunteer agrees to inform study doctor \& agrees to release medical information concerning for participation in the study
  • Living with a third party that will contact the study team if in case of alteration of consciousness during the first month of the study
  • Willing to undergo a Pf sporozoite challenge.
  • Willing to take curative treatment for malaria (Coartem®) \& any other medication which may be prescribed by a study doctor during study period
  • All volunteers agree to stay in the hospital during parts of the study (overnight after challenge, up to 15 days during follow up \& 3 days of Coartem® treatment)
  • Reachable (24/7) by mobile phone during the whole study period
  • Agreement not to participate in another study during the study period.
  • Agreement not to donate blood during the study period.
  • Available to attend all study visits
  • Willingness to undergo HIV, \& tests

Exclusion criteria

Exclusion Criteria:

  • History of malaria in the past 5 yrs
  • Plans to travel outside the Dar-es-salaam or Coast Region in first month (day 0-28) of the study
  • Plans to travel to highly malarious areas in the 6 months following the study period
  • Previous participation in malaria vaccine study \&/or positive serology for Plasmodium falciparum asexual crude extract antibodies above acceptable cut off established for the site.
  • History of arrhythmias or prolonged -interval or other cardiac disease
  • Positive family history of in the 1st \& 2nd degree relative for cardiac disease \<50 yrs old.
  • Volunteers unable to read \& write in English \& give written
  • Previous history of drug or alcohol abuse interfering with normal social function
  • A history of psychiatric disease
  • The use of chronic drugs, antibiotics, or other immune modifying drugs within three months of study onset (inhaled \& topical are allowed) \& during the study period
  • A history or confirmed sickle cell anemia, sickle cell trait, thalassemia , thalassemia trait or G6PD deficiency
  • Co-worker of the Ifakara Health Institute
  • Symptoms, physical signs \& laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, \& other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers
  • History of diabetes mellitus or cancer
  • An estimated, ten year risk of fatal cardiovascular disease of \<5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system
  • abnormalities in at screening
  • below 18 or above 30kg/m2
  • Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis or electrolytes
  • Positive , virus or Virus tests
  • Participation in any other clinical study within 30 days prior to the onset of the study or during the study period
  • Volunteers unable to be closely followed for social, geographic or psychological reasons
  • Known of other to Coaterm® or Malarone® including treatment taken by the volunteer that interferes with Coartem® or Malarone®
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Group 1 10,000 PfSPZ

    12 volunteers, ID PfSPZ Challenge total dose 10,000 PfSPZ administered by 2 injections of 50µL each.

    Biological: PfSPZ Challenge

  • Experimental
    Group 2 25,000 PfSPZ

    12 volunteers, ID PfSPZ Challenge total dose 25,000 PfSPZ administered in 4 injections of 10µL each.

    Biological: PfSPZ Challenge

  • Placebo comparator
    Controls - saline

    4 Volunteers, ID saline administered in 2 injections of 50µL each and 2 volunteers, ID saline administered in 4 injections of 10µL each.

    Biological: Saline

Interventions

  • BiologicalPfSPZ Challenge

    Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)

    Also known as: Plasmodium falciparum sporozoites

  • BiologicalSaline

    Saline

06

What researchers measure

Primary outcomes

  1. Number of volunteers positive in each group through day 28 of follow up.

    Thick smears will be performed according to a standard operating procedure. In short, 15 μL of whole blood will be distributed on standardized 3-well slides, providing an equal slide thickness for all smears. Slides are dried and stained with Giemsa. 200 fields per slide will be read at 1000X. Slides are considered positive if they contain 2 or more parasites per 200 fields.

    Time frame: 5 to 28 days

Secondary outcomes

  1. Time from inoculation until first positive parasitemia by thick smear in each volunteer in the two groups.

    Time frame: 5-28 days

  2. Time from inoculation to until first positive parasitemia by qRT-PCR in each volunteer in the two groups.

    qRT-PCR will be performed according to standard procedure described in Hermsen et al. Mol. Biochem. Parasitol. 2001; 118: 247-251. In short, qRT-PCR will be performed on the multicopy 18S ribosomal RNA gene. Cultured P. falciparum ring stage parasites are taken as a positive control. All samples are spiked with murine white blood cells, and a murine albumin gene PCR is used to determine efficacy of DNA isolation.

    Time frame: 5-28 days

  3. Kinetics of parasitemia in positive volunteers in the two groups as measured by qRT-PCR.

    Thick smear, malaria rapid diagnostic test and qRT-PCR samples will be taken from the same 3 mL EDTA vacutainer tube. Histidine Rich Protein 2 based malaria rapid diagnostic tests will be used in parallel to thick smears.

    Time frame: 5-28 days

  4. Occurrence or intensity of signs or symptoms in the two groups of volunteers

    Signs and symptoms will be recorded at all visits and whenever a trial volunteer reports signs or symptoms to the trial physician between visits. The following signs and symptoms will be solicited: fever, headache, malaise, fatigue, myalgia, arthralgia, nausea, vomiting, chills, diarrhea, abdominal pain (Verhage, Telgt, Bousema, Hermsen, van Gemert, van der Meer, \& Sauerwein 2005), chest pain, palpitations and shortness of breath.

    Time frame: 5 days to 6 months

07

Study locations

1 site
  • Bagamoyo Research and Training Center, Ifakara Health Institute
    Bagamoyo, Tanzania
08

References and documents

Publications

  • Shekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, Mpina M, Ali Juma O, Schindler T, Huber E, Gunasekera A, Manoj A, Simon B, Saverino E, Church LWP, Hermsen CC, Sauerwein RW, Plowe C, Venkatesan M, Sasi P, Lweno O, Mutani P, Hamad A, Mohammed A, Urassa A, Mzee T, Padilla D, Ruben A, Sim BKL, Tanner M, Abdulla S, Hoffman SL. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014 Sep;91(3):471-480. doi: 10.4269/ajtmh.14-0119. Epub 2014 Jul 28. PubMed 25070995 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Sep 2012 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2012
First posted
Feb 29, 2012
Start
Feb 2012
Primary completionActual
Sep 2012
CompletionActual
Aug 2013
Last update
Sep 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01540903
Lead sponsor
Sanaria Inc.
Collaborators
Ifakara Health Research and Development Centre, Swiss Tropical & Public Health Institute
Responsible party
Sponsor
First posted
Feb 29, 2012
Start date
Feb 2012
Primary completion
Sep 2012
Completion
Aug 2013
Last update
Sep 10, 2014

Study contacts

Salim Abdulla, MD, PhD
principal investigator · Ifakara Health Institute (IHI), Tanzania

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PfSPZ Challenge

Start the discussion